Cardax is a growth stage biopharmaceutical firm primarily centered on the event of prescribed drugs for power illnesses pushed by irritation. Cardax additionally markets a dietary complement for inflammatory well being.
San Francisco, California, Nov. 24, 2020 (GLOBE NEWSWIRE) — US Capital Global Securities LLC, an affiliate of US Capital World, is providing to eligible traders an funding alternative of as much as $10 million in membership models in US Capital World Cardax Most well-liked, LLC, a pooled funding automobile that can put money into convertible most popular inventory of Cardax, Inc. (“Cardax”). This providing is being made in reliance upon the exemption from securities registration afforded by Part 4(a)(2) of the Securities Act of 1933, as amended, pursuant to Rule 506(c) of Regulation D promulgated thereunder.
Headquartered in Honolulu, Hawaii, Cardax (OTCQB: CDXI) is a biopharmaceutical firm centered totally on growing prescribed drugs to soundly handle power inflammatory illness. Cardax additionally markets ZanthoSyn®, a physician-recommended dietary complement for well being and longevity.
With places of work in San Francisco and London, US Capital World is a full-service personal monetary group with a longtime observe report in offering company finance and asset administration. All securities are supplied via the group’s registered broker-dealer division, US Capital World Securities LLC.
David G. Watumull, President and CEO at Cardax, mentioned: “We’re very happy to be collaborating with US Capital World Securities on this $10 million providing. We imagine Cardax is at the moment at an inflection level in its development, and this financing is designed to advance our lead pharmaceutical candidate, CDX-101, over the subsequent 12 to 18 months from pre-clinical to scientific growth—a major worth creation occasion within the business.”
“It’s a actual pleasure to be serving Cardax as its lead placement agent on this providing,” mentioned Charles Towle, CEO at US Capital World Securities. “Cardax’s mission is to soundly fight power irritation—one of many main drivers of power illness, together with heart problems, metabolic illness, liver illness, arthritis, and growing older. If you’re eager about Cardax, the chance to take part on this $10 million funding is now open to eligible investors.”
About Cardax, Inc.
Cardax is a biopharmaceutical firm centered totally on growing prescribed drugs for illnesses pushed by irritation. The corporate additionally has a industrial enterprise unit that markets ZanthoSyn®, an astaxanthin dietary complement for inflammatory well being.* CDX-101, the corporate’s astaxanthin pharmaceutical candidate, is being developed for cardiovascular irritation and dyslipidemia, with a goal preliminary indication of extreme hypertriglyceridemia. CDX-301, the corporate’s zeaxanthin pharmaceutical candidate, is being developed for macular degeneration. The security and efficacy of the corporate’s pharmaceutical candidates haven’t been straight evaluated in scientific trials or confirmed by the FDA. www.cardaxpharma.com
About US Capital World
US Capital World Securities LLC (“USCGS”) is the FINRA-registered broker-dealer division of US Capital Global that acts as placement agent for growth-stage corporations, initiatives, and funding funds. Since 1998, the US Capital World group has been dedicated to offering small and decrease center market companies and traders with subtle debt, fairness, and funding alternatives normally obtainable solely to bigger center market corporations and institutional traders, utilizing the newest FinTech and RegTech innovation. US Capital World entities handle direct funding funds and supply wealth administration and capital increase companies. USCGS or its associates could present recommendation to, be compensated by, could produce other enterprise relationships with, or could on occasion purchase, maintain or promote a place within the securities of, the issuers talked about herein. Any such provide or solicitation shall be made solely pursuant to the confidential personal placement memorandum. View USCGS’ Kind CRS at www.uscgs.com/crs.html. 202011PR
To study extra about US Capital World Securities or this funding alternative, electronic mail Frank Villarreal at firstname.lastname@example.org or name +1 415-350-4092.
* This assertion has not been evaluated by the Meals and Drug Administration. This product just isn’t meant to diagnose, deal with, treatment, or forestall any illness.
Vanessa Guajardo US Capital World +1 415 889 1045 email@example.com